Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TetraVax-DV (National Institute of Allergy and Infectious Diseases)
- Development stage
- Unknown
- Lead developer
- Instituto Butantan
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
TetraVax-DV is a live attenuated tetravalent dengue vaccine developed by the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH). It is designed to provide protection against all four dengue virus serotypes (DENV-1, DENV-2, DENV-3, and DENV-4). The vaccine consists of four recombinant dengue virus strains (rDEN1Δ30, rDEN2/4Δ30, rDEN3Δ30/31, and rDEN4Δ30) attenuated primarily through a 30-nucleotide deletion in the 3'-untranslated region of the viral genome. Two primary formulations have been evaluated: TV003, which contains equal amounts (10³ PFU) of each serotype, and TV005, which features an increased dose (10⁴ PFU) of the DENV-2 component to enhance immunogenicity. The vaccine is administered as a single subcutaneous dose and has been licensed to several global manufacturers, including Instituto Butantan (as Butantan-DV), Panacea Biotec, and Merck, for late-stage development and commercialization.
- Brand names
- TetraVax-DV
- Other names
- TetraVax-DV-NIAIDLive Attenuated Tetravalent Dengue VaccineLATV
Beyond the preview
Go deeper on TetraVax-DV (National Institute of Allergy and Infectious Diseases).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TetraVax-DV (National Institute of Allergy and Infectious Diseases).